Cynata Therapeutics Ltd (CYP)
Australian Securities Exchange · Australia · prices in AUD · close of 21 Oct 2026
Key indicators
| Last close | AUD 0.011 |
|---|---|
| 52-week range | 0.009 – 0.435 |
| Return, 1 month / 3 months | +0.0% / −8.3% |
| Return, 1 year / 3 years | −96.0% / −90.8% |
| Trend | Below its 200-day average |
| RSI (14) | 46 |
| Volatility (1 year) | 279.7% |
| Worst drawdown (1 year) | -97.5% |
| Average daily value traded | 0.01M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Cynata Therapeutics is an Australian clinical-stage biotechnology company focused on regenerative medicine. It develops mesenchymal stem cell therapies using its Cymerus platform, a manufacturing approach based on induced pluripotent stem cells. The company works on treatments for inflammatory and vascular conditions, including graft-versus-host disease and critical limb ischemia, and partners with research and medical institutions to advance its cell therapy programmes. Cynata is based in Australia and its activities centre on developing and testing these stem cell products for clinical use.
On this site Cynata Therapeutics Ltd appears as a stock on the Australian Securities Exchange (Australia), code CYP, with prices in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Cynata Therapeutics Ltd (CYP) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.011 on 21 October 2026.
Its price-based Market X-Ray is 8 out of 100 (a weak price profile), ranking 1,794 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 96.0% and over the last three months it fell 8.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 1 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -94.0% | ||
| From 52-week high | -97.3% | ||
| Momentum | 15 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -8.3% | ||
| 6-month return | -96.8% | ||
| 12-month return, skipping the last month | -96.0% | ||
| Stability (higher is calmer) | 1 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 279.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -97.5% | ||
| Liquidity | 23 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M AUD | ||
| Zero-volume days | 10.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +0.0% |
| 3 months | −8.3% |
| 6 months | −96.8% |
| 1 year | −96.0% |
| 3 years | −90.8% |
| 5 years | −98.2% |
Signals
| 50-day / 200-day average | 0.011 / 0.183 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.001 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.